- Vaxxinity Inc (NASDAQ:VAXX) announced that the first subjects had been dosed in the Phase 1 clinical trial of UB-313, a vaccine targeting calcitonin gene-related peptide (CGRP), for the preventive treatment of migraine.
- The Phase 1 randomized, placebo-controlled, double-blind, multidose trial will enroll approximately 40 healthy volunteers in Belgium.
- The trial’s objectives are to evaluate safety, tolerability, and immunogenicity. Serum anti-CGRP antibody titers will measure immunogenicity. Pharmacodynamics of the immune response will be measured by the inhibition of the capsaicin-induced increase in dermal blood flow, an established model of target engagement in migraine.
- Price Action: VAXX shares are trading 2.09% higher at $2.20 on the last check Tuesday.
Lockheed Martin: Q2 Earnings Insights
Lockheed Martin (NYSE:LMT) reported its Q2 earnings results on Tuesday, July 19, 2022 at 07:30 AM.
Here's what investors need to know about the announcement.
